白细胞介素-32研究进展

 白细胞介素-32（IL-32） 是新近发现的一种细胞因子,体内外研究证明,它能通过抑制核转录因子-κB (NF-κB)、信号传导及转录激活因子3等通路抑制结肠癌及黑素瘤细胞的生长,促进其凋亡。此外,在慢性髓细胞性白血病、肉瘤、前列腺癌中能够通过不同的途径抑制肿瘤生长。     

酸性核磷酸蛋白32E研究进展

酸性核磷酸蛋白(ANP)32E是含有亮氨酸重复结构的蛋白质,参与广泛的生物学过程,其结构与ANP32A高度相似,通过磷酸化调节胞质运输,并可以抑制蛋白磷酸酶2A(PP2A)的活性.近期临床研究发现ANP32E在鼠纤维肉瘤中起抑癌基因的作用,而在乳腺癌发生中可能与肺转移相关,具体的机制尚未明确.     

酸性核磷酸蛋白32B在恶性肿瘤中的研究进展

酸性核磷酸蛋白32B(ANP32B)是高度保守的酸性富含亮氨酸的核磷蛋白32(ANP32)家族的成员之一,主要定位于细胞核内.ANP32B在细胞分化、增殖、凋亡、转录调控等多种生理过程中发挥重要节点作用.近年研究表明,ANP32B与多种恶性肿瘤的发生发展及肿瘤的预后密切相关.鉴于其在恶性肿瘤中的作用,ANP32B或可成...     

白细胞介素21抗肿瘤作用的研究进展

白细胞介素21(interleukin-21, IL-21) 是新近发现的具有免疫调节活性的细胞因子, 属于IL-2细胞因子家族新成员,主要由活化的CD4~+ T 细胞分泌,IL-21与其受体结合后可调节T细胞、自然杀伤(natural killer,NK)细胞和B细胞的增殖、分化和功能,有效增强机体的天然免疫及获得性免疫.在多种肿瘤模型中已证实,IL-21具有抗肿瘤活性,且Ⅱ期临床试验正在转移性黑素瘤和肾细胞癌中进行,其在恶性肿瘤治疗方面具有广泛的应用前景.本文对IL-21的抗肿瘤作用及其联合其他药物在未来肿瘤免疫治疗中的应用前景进行综述.     

樟芝抗肝癌机制研究进展

体外研究表明樟芝具有多个胞内靶点,影响着细胞生长、凋亡、血管新生以及侵袭和迁移。这些靶点包括肿瘤抑制基因、细胞周期调控蛋白、转录因子、血管新生以及迁移因子、凋亡和存活调节剂。此外,樟芝还具有免疫调节特性,可以通过增强免疫力间接地起到抗癌作用。     

Elevated serum concentration of interleukin-1 receptor antagonist (IL-1ra) is correlated to interleukin-6 and to hypoalbuminemia in cachectic patients with colorectal cancer

Background. The mechanisms leading to the development of cancer cachexia are still not well understood. Some important factors, including cytokines and growth factors, are involved, and recently, cytokines such as interleukin-1 and interleukin-6 have been reported to be involved as mediators of this disorder. Methods. In patients with colorectal cancer, serum concentrations of interleukin-1 receptor antagonist (IL-1ra) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA) and analyzed in relation to the patient's nutrition (in terms of albumin concentration [percentage of total protein] in the serum) and the tumor load. Results. The concentration of IL-1ra was significantly increased in cachectic patients compared with that in healthy volunteers and in the non-cachectic patients, and the concentration was correlated to the serum concentration of IL-6 and inversely correlated to the concentration of albumin (%). These concentrations, however, did not correlate to levels of tumor markers tested, ie, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9. Conclusion. It was shown that the serum concentration of IL-1ra was a useful indicator for cancer cachexia and hypoalbuminemia; IL-1ra seems to be produced by immune-regulating host cells rather than by neoplastic cells. Received: June 24, 1999 / Accepted: November 22, 1999     

沙利度胺对骨髓瘤细胞IL-6及其传导途径的影响

目的　探讨沙利度胺治疗难治复发性多发性骨髓瘤 (MM)的有效机制。方法　用双抗夹心法 (ELISA)动态检测MM患者血清白细胞介素 6 (IL 6 )水平 ,流式细胞仪检测瘤细胞表面IL 6受体 (IL 6R)的表达 ,RT PCR半定量法检测IL 6Rβ亚单位mRNA的表达。 结果　口服 2 0 0mg/d沙利度胺前 ,MM患者血清IL 6水平为 5 6 4.8± 319.4ng/L ,瘤细胞表面IL 6R阳性率为 33.6 % ;口服 2 0 0mg/d沙利度胺后第 14天 ,IL 6水平为 5 6 0 .3± 414.8ng/L ,瘤细胞表面IL 6R阳性率为 31.8% ,分别与口服沙利度胺前比较 ,差异无显著性 (P >均 0 .0 5 )。口服 40 0mg/d沙利度胺第 14,2 8,42 ,5 6 ,84天 ,IL 6水平分别为 5 16 .7± 131.9、42 6 .7± 180 .4、387.9± 187.4、35 0 .1± 85 .5和 2 12 .3± 92 .5ng/L ,瘤细胞表面IL 6R阳性率分别为 2 8.5 %、2 4.3%、2 1.3%、12 .6 %和 10 .1% ,均分别低于口服 2 0 0mg/d沙利度胺前IL 6水平或瘤细胞表面IL 6R阳性率 (P <0 .0 5或P <0 .0 1) ;口服 2 0 0mg/d沙利度胺前及口服第 14天的IL Rβ亚单位mRNA比值分别为 7.8和 6 .9,二者差异无显著性 (P >0 .0 5 ) ;口服沙利度胺 40 0mg/d第 14,2 8天IL Rβ亚单位mRNA的比值分别为 5 .3和 2 .7,与口服 2 0 0mg/d沙利度胺前的比较 ,差异有显著性 (P     

Foxml在细胞周期和肿瘤中的研究进展

Foxml是Fox家族中转录因子之一,特异性表达于增殖期细胞中,在细胞终末分化时消失。Foxml与细胞生长密切相关,主要通过抑制细胞周期素依赖性激酶抑制剂介导细胞增殖,还参与生长激素介导的细胞增殖。许多恶性肿瘤细胞株中Foxml过表达,可能是多种肿瘤增殖所必需的一种原癌基因。由于缺乏杂合性和拷贝数目的改变,上调的Foxml充分诱导染色体的不稳定。随着信号通路的增强,Foxml诱导染色体不稳定得到明显增强和累积。Foxml可能是治疗人类肿瘤的新靶点。     

Clinical implications of interleukins-31, 32, and 33 in gastric cancer

BACKGROUNDGastric cancer (GC) is one of the most common malignancies in China with a high morbidity and mortality.AIMTo determine whether interleukin (IL)-31, IL-32, and IL-33 can be used as biomarkers for the detection of GC, via evaluating the correlations between their expression and clinicopathological parameters of GC patients.METHODSTissue array (n = 180) gastric specimens were utilised. IL-31, IL-32, and IL-33 expression in GC and non-GC tissues was detected immunohistochemically. The correlations between IL-31, IL-32, and IL-33 expression in GC and severity of clinicopathological parameters were evaluated. Survival curves were plotted using the Kaplan-Meier method/Cox regression. Circulating IL-31, IL-32, and IL-33 were detected by ELISA.RESULTSWe found that the expression levels of IL-31, IL-32, and IL-33 were all lower in GC than in adjacent non-GC gastric tissues (P < 0.05). IL-33 in peripheral blood of GC patients was significantly lower than that of healthy individuals (1.50 ± 1.11 vs 9.61 ± 8.00 ng/mL, P <0.05). Decreased IL-31, IL-32, and IL-33 in GC were observed in younger patients (< 60 years), and IL-32 and IL-33 were lower in female patients (P < 0.05). Higher IL-32 correlated with a longer survival in two GC subgroups: T4 invasion depth and TNM I-II stage. Univariate/multivariate analysis revealed that IL-32 was an independent prognostic factor for GC in the T4 stage subgroup. Circulating IL-33 was significantly lower in GC patients at TNM stage IV than in healthy people (P < 0.05).CONCLUSIONOur findings may provide new insights into the roles of IL-31, IL-32, and IL-33 in the carcinogenesis of GC and demonstrate their relative usefulness as prognostic markers for GC. The underlying mechanism of IL-31, IL-32, and IL-33 actions in GC should be further explored.     

Foxm1在细胞周期和肿瘤中的研究进展

 Foxm1是Fox家族中转录因子之一,特异性表达于增殖期细胞中,在细胞终末分化时消失。Foxm1与细胞生长密切相关,主要通过抑制细胞周期素依赖性激酶抑制剂介导细胞增殖,还参与生长激素介导的细胞增殖。许多恶性肿瘤细胞株中Foxm1过表达,可能是多种肿瘤增殖所必需的一种原癌基因。由于缺乏杂合性和拷贝数目的改变,上调的Foxm1充分诱导染色体的不稳定。随着信号通路的增强,Foxm1诱导染色体不稳定得到明显增强和累积。Foxm1可能是治疗人类肿瘤的新靶点。     

乙肝病毒相关肝细胞肝癌与IL-32表达相关性研究

目的 肝细胞肝癌(hepatocellular carcinoma,HCC)是最常见的恶性肿瘤之一,白细胞介素(interleukin,IL)-32是新发现的一种细胞因子,在HCC中的研究较少.本研究探讨其在乙肝病毒(heptitis B virus,HBV)相关HCC患者外周血、肝组织以及体外培养的HepG2、HepG2 2.15细胞株中表达水平的变化.方法 选择2013-01-01-2016-06-30在南通市第三人民医院住院的HBV相关肝硬化(liver cirrhosis,LC)27例和HBV-HCC 29例作为研究对象,选择体检健康者17名作为对照组,采用酶联免疫吸附方法检测外周血IL-32.选择外科手术切除HBV-HCC、癌旁LC标本20份,采用免疫组织化学的方法检测肝组织中IL-32表达情况.对HepG2、HepG2 2.15细胞进行培养,72 h后采集上清液,采用蛋白印迹法检测IL-32.结果 HBV-HCC患者外周血IL-32表达水平为(479.46±204.46) ng/L,高于HBV-LC患者(333.61±162.76) ng/L;HBV-LC患者高于健康对照组为(75.58±9.90) ng/L,P<0.005;HBV-HCC癌组织中IL-32表达水平高于癌旁LC组织,Z=2.725,P=0.006;HepG2细胞株与HepG2.2.15细胞株培养72 h后,上清液中未能检测到IL-32.结论 IL-32在HBV相关HCC外周血、HCC癌组织中均处于过度表达状态,在HBV-HCC的发生发展过程中起到一定的作用.     

Relationship of Serum Interleukin-18 and Interleukin-12 Levels with Clinicopathology in Renal Cell Carcinoma

Objective:To investigate the relationship between serum interleukin-18 and interleukin-12 levels and clinicopathology of renal cell carcinoma.Methods:Peripheral blood samples were obtained from 20 healthy volunteers and 60 patients with renal cell carcinoma before curative surgery.IL-12 and IL-18 levels were determined by enzyme-linked immunosorbent assay.Results:Mean serum IL-12 and IL-18 levels were significantly higher in patients with renal cell carcinoma compared with healthy volunteers(P<0.05)and mean serum IL-12 and IL-18 levels increased in patients as the pathologic stage progressed.A positive correlation was observed between serum IL-12 and IL-18 levels(P<0.05).In patients with renal cell carcinoma,increasing serum IL-12 and IL-18 levels correlated with pathological stage and Fuhrman grade.Conclusion:Serum IL-12 and IL-18 might be useful tumor markers in patients with renal cell carcinoma.     

Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors

Summary Interleukin-6 (IL-6) is a multifunctional cytokine which plays a role in the stimulation, inhibition, differentiation, and regulation of cell growth. IL-6 has been shown to act as an autocrine growth factor in several tumors, and is expressed by a variety of tumors. IL-6 also exhibits a regulatory role in the hypothalamopituitary axis. It is produced by both the hypothalamus and the pituitary, and it induces the secretion of anterior pituitary hormones. Because of the regulatory role of IL-6 in tumor growth and its involvement in the pituitary, we decided to evaluate IL-6 and IL-6 receptor expression in pituitary tumors. For this purpose we utilized complimentary cDNA probes specific for the IL-6 and IL-6 receptor mRNA, as well as monoclonal anti-IL-6 antibodies for immunohistochemical analysis.Our results show that the IL-6 gene is expressed in the normal pituitary tissue. However, the non-functioning and functioning pituitary tumors such as the prolactin and growth hormone secreting tumors express increased levels of the IL-6 gene. The IL-6 receptor gene was only expressed in the prolactin secreting and non-functioning pituitary tumors. These results show that the IL-6 and IL-6 receptor gene expression is enhanced in pituitary tumors, thus suggesting a possible role of IL-6 in the pathogenesis of these tumors.     

转录因子 AP-2在泌尿生殖系统肿瘤中的研究进展

转录因子激活蛋白-2（AP-2）在肿瘤细胞的增殖、分化、癌变及化疗耐药方面扮演着重要角色。AP-2在不同泌尿生殖系统肿瘤组织中分别呈现出抑癌或促癌的双向调控效应。研究 AP-2在泌尿生殖系统肿瘤中的作用及作用机制可为相关肿瘤的诊治提供新的思路和方向。     

IL-12与IL-18在胃癌组织中的表达及其临床意义

目的：探讨胃癌组织中白介素-12（IL-12）与白介素-18（IL-18）的表达，及其与胃癌临床病理特征、血管生成及预后的关系。方法：选取50例胃癌标本，通过免疫组化检测IL-12与IL-18在胃癌组织中的表达，显微图像分析系统测定微血管密度。结果：IL-12与IL-18在胃癌中的阳性表达率分别为44％（22／50）和26％（13／50），IL-12与病理分化（P=0．029）、浸润深度（P=0．002）、淋巴结转移（P=0．002）、远处转移（P=0．003）和TNM分期（P=0．005）相关，IL-18与远处转移密切相关（P=0．001）；多因素生存分析显示IL-12、MVD和T分期是胃癌的独立预后因素。结论：IL-12和IL-18阳性表达与肿瘤进展和转移有关，IL-12是提示胃癌患者预后不良的独立因素。     

Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma

Interleukin-1 (IL-1) is a cytokine involved in the maturation and proliferation of B cells and plays a significant role in the development of lytic bone lesions, a major clinical feature of multiple myeloma (MM) patients. Genes that regulate products involved in the immune system are highly polymorphic and contribute to inter-individual differences that can influence the genetic predisposition and progression of particular diseases and cancers. In this study, we investigated the correlation between the single nucleotide polymorphisms IL1A -889, IL1B -511, IL1B +3954, IL1RN Mspa1 +11100 and susceptibility to MM in 74 patients and 160 controls. We found that individuals possessing IL1A -889 CT polymorphism had a higher risk in developing MM. Moreover, genotypes IL1B -511 CC, IL1B +3954 CC, IL-1RN Mspa1 +11100 CC and the combination of IL 1B +3954 CC with IL1B -511 CC or IL-1RN Mspa1 +11100 CC exerted a protective effect in individuals possessing them.     

白细胞介素22在恶性肿瘤中的研究进展

白细胞介素22（IL-22）是白细胞介素10家族中的一员,与IL-10具有相似的结构和免疫作用,主要由Th22、Th1、Th17细胞、固有淋巴细胞（ILCs）、γδT细胞和NKT细胞分泌。IL-22在自身免疫性疾病、恶性肿瘤和感染性疾病中发挥重要作用。有关IL-22细胞因子在各种恶性肿瘤中的作用机制,仍是目前研究的热点。研究IL-22在恶性肿瘤中的表达及作用机制,为恶性肿瘤的治疗和预防提供了新的思路。本文从IL-22的发现、结构特点及其在恶性肿瘤中的作用进行综述。      

肺癌患者血清白细胞介素6，8，18的测定及其临床意义

 目的 探讨血清白细胞介素6，8，18（IL-6，IL-8，IL-18）与肺癌的发生、发展、转移、疗效及预后的关系。方法 采用双抗体夹心酶联免疫吸附试验（ELISA法）检测56例肺癌患者、18例肺结核患者治疗前后及40例健康人的血清IL-6，IL-8，IL-18含量，并进行比较分析。结果 肺癌患者血清IL-6，IL-8，IL-18水平明显高于正常人和肺结核患者（P＜0.01），且与临床分期及治疗效果有关（P＜0.05或＜0.01），与病理类型无关（P＞0.05）。结论 血清IL-6，IL-8，IL-18水平在一定程度上可反映肺癌发生、发展、转移情况及治疗效果，联合检测IL-6，IL-8，IL-18，对肺癌的诊断、治疗及预后评价有重要意义。     

婴幼儿皮肤血管瘤P-32放射治疗的临床观察

目的:探讨P-32放射治疗婴幼儿皮肤血管瘤的临床效果及不良反应.方法:观察38例婴幼儿P-32放射治疗后的治疗效果及不良反应.结果:P-32放射治疗婴幼儿血管瘤一次治愈率76.3%,有效率100%.治疗中要及时注意皮肤局部损伤情况.结论:P-32放射治疗婴幼儿皮肤血管瘤方法有效,不良反应.